^
    Back
    Association details:
    Biomarker:TSC2 A736V
    Cancer:Neurofibrosarcoma
    Drug:everolimus (mTOR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

    Published date:
    05/19/2021
    Excerpt:
    Table summarizes matched therapies in responders....Malignant peripheral nerve sheath tumor...TSC2: A736V...Temsirolimus + cyclophosphamide + vinorelbine – PR, 13 mo. Everolimus - PD
    DOI:
    10.1200/JCO.2021.39.15_suppl.11538